Biologically Active Small Molecules

A dual inhibitor of mPGES-1 (IC₅₀= 1.3 &muM) and 5-LO (IC₅₀ = 1.0 &muM) effectively inhibits PGE2 and LT synthesis in both cell free and intact cell assays.

A dual inhibitor of mPGES-1 (IC₅₀= 1.3 &muM) and 5-LO (IC₅₀ = 1.0 &muM) effectively inhibits PGE2 and LT synthesis in both cell free and intact cell assays.

A potent and selective inhibitor of sPLA2 that exhibits 95% inhibition (XI(50)=0.003) of sPLA2 without affecting the activities of cPLA2 or iPLA2.

A potent and selective inhibitor of sPLA2 that exhibits 95% inhibition (XI(50)=0.003) of sPLA2 without affecting the activities of cPLA2 or iPLA2.

A potent and selective inhibitor of sPLA2 that exhibits 95% inhibition (XI(50)=0.003) of sPLA2 without affecting the activities of cPLA2 or iPLA2.

A potent and selective inhibitor of sPLA2 that exhibits 95% inhibition (XI(50)=0.003) of sPLA2 without affecting the activities of cPLA2 or iPLA2.

An activator of SIRT1 that decreases TNF-&alpha levels from 325 pg/ml (control) to 104 and 53 pg/ml at 20 and 60 &microM, respectively exhibits a significant dose-dependent effect on fat mobilization in differentiated adipocytes.

An activator of SIRT1 that decreases TNF-&alpha levels from 325 pg/ml (control) to 104 and 53 pg/ml at 20 and 60 &microM, respectively exhibits a significant dose-dependent effect on fat mobilization in differentiated adipocytes.

An activator of SIRT1 that decreases TNF-&alpha levels from 325 pg/ml (control) to 104 and 53 pg/ml at 20 and 60 &microM, respectively exhibits a significant dose-dependent effect on fat mobilization in differentiated adipocytes.

An activator of SIRT1 that decreases TNF-&alpha levels from 325 pg/ml (control) to 104 and 53 pg/ml at 20 and 60 &microM, respectively exhibits a significant dose-dependent effect on fat mobilization in differentiated adipocytes.

A selective PPARd agonist that acts as a partial agonist (EC50 = 53 nM) in transactivation assays and as a full agonist (EC50 = 30 nM) in the oxidation of free fatty acid increases HDL levels, decreases LDL and TG levels, and improves insulin

A selective PPARd agonist that acts as a partial agonist (EC50 = 53 nM) in transactivation assays and as a full agonist (EC50 = 30 nM) in the oxidation of free fatty acid increases HDL levels, decreases LDL and TG levels, and improves insulin